Skip to content
Sign up to receive our free weekday morning edition, and you'll never miss a scoop.
The Senate’s adherence to the blue slip tradition is standing in the way of Alina Habba and Lindsey Halligan’s nominations. But the Senate GOP aren’t budging.

Senate Republicans stand by the blue slip

The Senate’s adherence to the blue slip tradition is standing in the way of Alina Habba and Lindsey Halligan’s nominations. But Senate Republicans aren’t budging.

Republican senators are standing by the longstanding practice of allowing senators to have veto power on home-state nominees, even amid twin setbacks for President Donald Trump’s U.S. attorney picks.

Over the past two weeks, courts have ruled that Halligan, acting U.S. attorney for the Eastern District of Virginia, and Habba, acting U.S. attorney for New Jersey, were improperly nominated to their roles. And in the Senate, both nominees lacked sign-off from their Democratic home state senators.

For now, Senate Republicans are standing by Senate Judiciary Committee Chair Chuck Grassley (R-Iowa) and his defense of the blue slip. While the practice is benefiting blue-state Democrats at this time, Republicans note that it’s helped them under Democratic administrations.

“It’s proved to be very useful in previous administrations by Republicans when we were in the minority,” Sen. John Cornyn (R-Texas) said.

“I support Sen. Grassley and his support of the blue slip,” Sen. Shelley Moore Capito (R-W.Va.) added. “I’d like to see the preservation of it.”

It’s a rare instance of daylight between Trump and Senate Republicans. The president has railed against the tradition and sees it as an obstacle to getting his nominees approved.

Grassley’s team alluded to the practice when commenting on the news that a federal appeals court invalidated Habba’s nomination.

“U.S. Attorney and district judge nominees without blue slips don’t have the votes to get through committee or pass on the Senate floor,” Grassley spokesperson Clare Slattery said in a statement.

Presented by AstraZeneca

The 340B program was created to help patients. Instead, it’s helping hospitals earn massive profits. The 340B Rebate Model Pilot uses rapid verification of existing data to prevent duplicate discounts, strengthening program transparency and efficiency. Urge HHS to implement the Rebate Model Pilot and ensure 340B functions as intended. Get the facts.

Editorial photos provided by Getty Images. Political ads courtesy of AdImpact.

Presented by AstraZeneca

The 340B program is supposed to help vulnerable patients—but without strong safeguards, it’s siphoning away funds that could be used for free and charitable medicine. The 340B Rebate Model Pilot improves program integrity, preventing duplicate discounts and strengthening accountability. Urge HHS to implement the pilot today. Learn why it matters.

Welcome to Punchbowl News AM! We're glad to have you here.

Want to get more of what you need? Share a bit more about yourself to help us tailor your reader experience.

Thank you for signing up!

Thank you for signing up!

 

We have sent you a confirmation email. Please follow the provided instructions to complete your sign-up.

Thank you for confirming! You are now subscribed to the Punchbowl News AM list.

You're subscribed! Welcome to the community.